Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

Author information

1
Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX 77030, USA. hshen@tmhs.org

Abstract

PURPOSE:

RNA interference has the potential to specifically knockdown the expression of target genes and thereby transform cancer therapy. However, lack of effective delivery of siRNA has dramatically limited its in vivo applications. We have developed a multistage vector (MSV) system, composed of discoidal porous silicon particles loaded with nanotherapeutics, that directs effective delivery and sustained release of siRNA in tumor tissues. In this study, we evaluated therapeutic efficacy of MSV-loaded EphA2 siRNA (MSV/EphA2) with murine orthotopic models of metastatic ovarian cancers as a first step toward development of a new class of nanotherapeutics for the treatment of ovarian cancer.

EXPERIMENTAL DESIGN:

Tumor accumulation of MSV/EphA2 and sustained release of siRNA from MSV were analyzed after intravenous administration of MSV/siRNA. Nude mice with metastatic SKOV3ip2 tumors were treated with MSV/EphA2 and paclitaxel, and therapeutic efficacy was assessed. Mice with chemotherapy-resistant HeyA8 ovarian tumors were treated with a combination of MSV/EphA2 and docetaxel, and enhanced therapeutic efficacy was evaluated.

RESULTS:

Treatment of SKOV3ip2 tumor mice with MSV/EphA2 biweekly for 6 weeks resulted in dose-dependent (5, 10, and 15 μg/mice) reduction of tumor weight (36%, 64%, and 83%) and number of tumor nodules compared with the control groups. In addition, tumor growth was completely inhibited when mice were treated with MSV/EphA2 in combination with paclitaxel. Furthermore, combination treatment with MSV/EphA2 and docetaxel inhibited growth of HeyA8-MDR tumors, which were otherwise resistant to docetaxel treatment.

CONCLUSION:

These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer.

PMID:
23386691
PMCID:
PMC3618564
DOI:
10.1158/1078-0432.CCR-12-2764
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center